Emerging options for the treatment of melanoma - focus on ipilimumab.

Immunotargets Ther · 2014 · PMC4918235 · PMID 27482517

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Data from several Phase II studies have demonstrated a positive trend towards higher rates of disease control and OS in those patients with grade >2 irAEs.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.